Selection of personalized cancer therapy regimens using...

Details Selection of personalized cancer therapy regimens using... Selection of personalized cancer therapy regimens using...

C - Chemistry, Metallurgy

12

Q

C12Q 1/68 (2006.01) C12Q 1/02 (2006.01) C12Q 1/48 (2006.01) C40B 30/00 (2006.01) C07H 21/02 (2006.01) C12N 9/12 (2006.01) C12N 15/11 (2006.01)

Patent

CA 2643886

Methods for screening cells obtained from a subject for aberrant kinase activity are disclosed. The methods include placing cells isolated from the subject in contact with a set of siRNAs, wherein each individual siRNA is at an addressable location on the array and specifically inhibits expression of a tyrosine kinase. The siRNA is introduced into the blood cells or bone marrow cells by electroporation. After introduction of the siRNA, the cells are then assayed for proliferation and/or viability as compared to a control. A decreased proliferation and/or viability of the cells as compared to a control identifies a siRNA that inhibits the proliferation and/or viability of the cells, thus identifying the tyrosine kinase having aberrant tyrosine kinase activity in the subject.

Affiliated with

Also associated with

Rating

Selection of personalized cancer therapy regimens using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selection of personalized cancer therapy regimens using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selection of personalized cancer therapy regimens using... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2049658